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Cancer arises in the twenty-first century as one of the
leading causes for mortality in the western civilization.
In the last decades, several genes were identified as
important players in the transformation of a normal cell
into a tumor cell. Therefore, modulation of those genes
is a promising strategy for cancer treatment. Gene
downregulation can be mediated by small-interfering
RNA (siRNA), 21-23 nucleotides long double strand of
RNA, which has the potential to inhibit the expression
of a target gene through specific cleavage of perfectly
complementary mRNA. However, the clinical use of
these molecules has been impaired by their unfavourable
pharmacokinetics profile and low intracellular
accumulation.
In order to address this issue, we have developed a
novel targeted sterically stabilized lipid-based nanoparti-
cle characterized by high siRNA encapsulation effi-
ciency, efficient protection of siRNA, average size
around 200 nm, and charge close to neutrality. Overall,
these are nanoparticles that present adequate features
for systemic administration.
Our results have shown that the targeted nanoparti-
cles were specifically internalized by human cancer cells
(MDA-MB-435 and MDA-MB-231) and endothelial
cells (HMEC-1). In experiments performed with green
fluorescent protein (GFP)-overexpressing human cancer
cell lines, specific downregulation of GFP, both at the
protein and mRNA levels, was further observed with the
targeted nanoparticle but not with the non-targeted
counterpart. As the developed nanoparticle is adequate
for the encapsulation and delivery of any siRNA
sequence, studies with a siRNA against a therapeutic
molecular target are now ongoing.
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